Sensei Biotherapeutics (NASDAQ:FTH) Stock Rating Reaffirmed as “Buy” by BTIG Research

Sensei Biotherapeutics (NASDAQ:FTH)‘s stock had its “buy” rating reiterated by analysts at BTIG Research in a research note issued on Tuesday, Benzinga reports. They presently have a $55.00 price target on the stock. BTIG Research‘s price objective points to a potential upside of 226.80% from the stock’s current price.

Several other research firms have also commented on FTH. TD Cowen assumed coverage on shares of Sensei Biotherapeutics in a research note on Wednesday, September 9th. They set a “buy” rating for the company. Wall Street Zen downgraded shares of Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, September 26th. Citizens Jmp assumed coverage on Sensei Biotherapeutics in a report on Monday, July 20th. They set an “outperform” rating and a $51.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $60.00 target price on shares of Sensei Biotherapeutics in a research report on Tuesday, August 11th. Finally, William Blair started coverage on shares of Sensei Biotherapeutics in a research report on Friday, October 16th. They set an “outperform” rating for the company. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $56.25.

Sensei Biotherapeutics Stock Performance

NASDAQ FTH opened at $16.83 on Tuesday. The firm has a market capitalization of $434.89 million, a PE ratio of -0.12 and a beta of -0.29. The business has a fifty day moving average of $29.91. Sensei Biotherapeutics has a fifty-two week low of $7.45 and a fifty-two week high of $42.14.

Sensei Biotherapeutics (NASDAQ:FTH) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share for the quarter, topping analysts’ consensus estimates of ($5.04) by $2.20. As a group, analysts forecast that Sensei Biotherapeutics will post -13.69 EPS for the current fiscal year.

Institutional Investors Weigh In On Sensei Biotherapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Citadel Advisors LLC purchased a new position in shares of Sensei Biotherapeutics during the 2nd quarter worth approximately $307,000. Alyeska Investment Group L.P. acquired a new stake in shares of Sensei Biotherapeutics during the 2nd quarter valued at $3,610,000. Vivo Capital LLC acquired a new position in shares of Sensei Biotherapeutics in the 1st quarter valued at $22,758,000. Bank of America Corp DE grew its stake in Sensei Biotherapeutics by 10,692.5% during the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after buying an additional 32,719 shares during the last quarter. Finally, Stempoint Capital LP bought a new position in Sensei Biotherapeutics in the 1st quarter valued at $4,188,000. 10.50% of the stock is owned by institutional investors and hedge funds.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is designed to activate and direct the immune system against tumors, with an emphasis on treatments that may address immune-suppressive mechanisms in the tumor microenvironment.

Sensei’s pipeline has included SNS-101, an investigational antibody targeting VISTA, an immune checkpoint believed to limit anti-tumor immune responses, and SNS-301, an investigational cancer vaccine developed using the company’s ImmunoPhage platform.